Brainstorm Cell Therapeutics Inc. (BCLI): Analysis on simple moving average

0
29

Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) changes shares on Wednesday trading session, with a change of -2.09% or -$0.28 shares. The trading starts at $13.39 and closed at $13.39 throughout the day. The trading session low price was $12.30 and day high was $13.68 on Wednesday, August 05. After the session, the Healthcare sector daily volume shifted to 1.02 million while its average volume is 736.38K. In other hand, the BCLI market cap reached to $405.36M. While, its current target price is $17.17.

On July 6, 2020, BRIEF-Lineage Cell Therapeutics Announces Extension Of Opregen Development Grant From Israel Innovation Authority. According to the news reported on Reuters, * LINEAGE CELL THERAPEUTICS ANNOUNCES EXTENSION OF OPREGEN DEVELOPMENT GRANT FROM ISRAEL INNOVATION AUTHORITY Source text for Eikon: Further company coverage:

Checking out the performance report which defines the increase or decrease of prices for a specific period. For the last 5 trading sessions, its performance is down -5.62% and up 5.05% for month. Its quarterly performance was 94.51% above, while its half year performance is up 221.32%. BCLI yearly performance stood at positive 257.22% and rise 206.31% for year-to-date. Current recommendation for Brainstorm Cell Therapeutics Inc. is 2.00.

Earnings per share or EPS is an important financial measure, which defines the profitability of a company. BCLI EPS (TTM) for 12-month is -1.10. EPS for this year is -52.20%, while for the next year its value is -0.70. Its EPS Q/Q reached -18.80%. It has an EPS of -9.40% down for past five years.

Let’s take a look on the analyst recommendations on BCLI for the current month and previous month. For the current month, 2 of 2 analysts recommend stock as Buy while 0 as Sell, 0 as overweight, 0 as underweight and 0 as Hold. As compared with the previous month ratings, 0 analysts participate in stock recommendation. Out of 0, 0 rated it sell, 0 rated it as Buy and 0 as Hold Ratings. On the other hand, target price ranges from $14.00 – $20.00. Average target price for BCLI was reached at $17.17.

The insider ownership moved to 1.30% and institutional holding shifted to 13.70%.

The company posted an EPS (TTM) of -1.10. According to the most recent quarter report on (Sep 2020), 3 analysts estimated an average EPS of -0.26, while -0.25 EPS posted a year ago period. Analyst Estimated EPS for BCLI published in the report was -$0.3 – -$0.22 during the same period. Comparing with last year, the average estimated EPS was -0.25 which is equal to -0.25 which was posted for recent quarter EPS.

A brief look on simple moving average (SMA) that determines the market price can impact a market. The SMA for BCLI rise 101.03% for period of 200 days. SMA for 50 days was 14.95% which is showing green signal, while SMA-20 was -7.58%. The moving average value for Brainstorm Cell Therapeutics Inc. (BCLI) is 3.16M and 15.00% for 200 and 50 days respectively.

Let’s take a look on the insider transactions, in which multiple shareholders are showing interest in BCLI stock. On Jul 16, Setboun David, EVP and COO, bought 5,000 trading shares at the cost of $12.95, which valued at 64740.0. On Jul 16, ACC International Holdings Ltd, Member of 10% owner group, sold 7,823 shares at the cost of $13.47, with total shares of 67,053. On Jul 15, Abbhi Sankesh, Director, bought 46,779 shares at the cost of 12.99. After this transaction, Abbhi Sankesh total shares reached to 2,164,530 which valued at 0.61 million.